If you follow the last link provided in my post, I’ve previously made some comparisons between the two programs, with PYC appearing to have some advantages.
Obviously Regulus is at least a couple of years ahead of PYC.
One positive for PYC is that as the Regulus program advances, it provides a clearer view of the regulatory pathway ahead (both FDA and EMA) for PYC’s program.
ADPKD is potentially a very large global market so there is room for multiple players.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.020(1.69%) |
Mkt cap ! $679.4M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.20 | $1.16 | $37.12K | 31.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 13419 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 6037 | 5 |
View Market Depth
| Last trade - 12.21pm 16/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |